m8891

M8891 is a proprietary, orally available, potent, selective, and reversible small molecule inhibitor of methionine aminopeptidase 2 (MetAP2), an enzyme that cleaves the amino-terminal methionine residue from nascent proteins. By inhibiting MetAP2, M8891 disrupts endothelial cell growth and proliferation during tumor angiogenesis, resulting in antiangiogenic and antitumor activity. Preclinical studies have shown that M8891 inhibits new blood vessel formation and tumor cell proliferation. It has also demonstrated strong antitumor effects in combination with VEGFR-targeted tyrosine kinase inhibitors in renal cell carcinoma models. The drug is being developed primarily for oncology indications such as advanced solid tumors and clear cell renal cell carcinoma[1][2][4][5][7].

Other names

methionine aminopeptidase 2 inhibitorMetAP2 inhibitorMetAP-2 inhibitorMetAP 2 inhibitor